Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.76
ARAY's Cash to Debt is ranked higher than
61% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ARAY: 0.76 )
ARAY' s 10-Year Cash to Debt Range
Min: 0.76   Max: No Debt
Current: 0.76

Equity to Asset 0.16
ARAY's Equity to Asset is ranked lower than
53% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ARAY: 0.16 )
ARAY' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.69
Current: 0.16

-0.65
0.69
F-Score: 5
Z-Score: 0.70
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.32
ARAY's Operating margin (%) is ranked higher than
62% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 5.53 vs. ARAY: -6.32 )
ARAY' s 10-Year Operating margin (%) Range
Min: -586.2   Max: 1.28
Current: -6.32

-586.2
1.28
Net-margin (%) -12.15
ARAY's Net-margin (%) is ranked higher than
60% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. ARAY: -12.15 )
ARAY' s 10-Year Net-margin (%) Range
Min: -584.5   Max: 2.56
Current: -12.15

-584.5
2.56
ROE (%) -51.70
ARAY's ROE (%) is ranked higher than
53% of the 440 Companies
in the Global Medical Devices industry.

( Industry Median: 5.22 vs. ARAY: -51.70 )
ARAY' s 10-Year ROE (%) Range
Min: -68.25   Max: 4.2
Current: -51.7

-68.25
4.2
ROA (%) -9.61
ARAY's ROA (%) is ranked higher than
61% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.73 vs. ARAY: -9.61 )
ARAY' s 10-Year ROA (%) Range
Min: -72.32   Max: 1.72
Current: -9.61

-72.32
1.72
ROC (Joel Greenblatt) (%) -49.61
ARAY's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 470 Companies
in the Global Medical Devices industry.

( Industry Median: 9.36 vs. ARAY: -49.61 )
ARAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -383.97   Max: 15.55
Current: -49.61

-383.97
15.55
Revenue Growth (3Y)(%) 9.60
ARAY's Revenue Growth (3Y)(%) is ranked higher than
84% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ARAY: 9.60 )
ARAY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7   Max: 133.5
Current: 9.6

-7
133.5
EBITDA Growth (3Y)(%) -7.20
ARAY's EBITDA Growth (3Y)(%) is ranked lower than
105% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ARAY: -7.20 )
ARAY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 50.4
Current: -7.2

0
50.4
EPS Growth (3Y)(%) 2.20
ARAY's EPS Growth (3Y)(%) is ranked higher than
76% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ARAY: 2.20 )
ARAY' s 10-Year EPS Growth (3Y)(%) Range
Min: 2.2   Max: 91.3
Current: 2.2

2.2
91.3
» ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ARAY Guru Trades in Q4 2013

Jim Simons 447,523 sh (New)
Steven Cohen 1,007,200 sh (+54.95%)
Chuck Royce 1,468,500 sh (+1.73%)
PRIMECAP Management 8,301,600 sh (unchged)
» More
Q1 2014

ARAY Guru Trades in Q1 2014

Chuck Royce 1,560,000 sh (+6.23%)
PRIMECAP Management 8,785,500 sh (+5.83%)
Steven Cohen 814,200 sh (-19.16%)
Jim Simons 247,640 sh (-44.66%)
» More
Q2 2014

ARAY Guru Trades in Q2 2014

Jim Simons 529,123 sh (+113.67%)
Chuck Royce 1,690,500 sh (+8.37%)
Steven Cohen 1,028,900 sh (unchged)
PRIMECAP Management 8,690,700 sh (-1.08%)
» More
Q3 2014

ARAY Guru Trades in Q3 2014

Paul Tudor Jones 36,179 sh (New)
Jim Simons 1,312,023 sh (+147.96%)
Steven Cohen 1,277,500 sh (+24.16%)
PRIMECAP Management 8,665,700 sh (-0.29%)
Chuck Royce 1,658,500 sh (-1.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out 0.37%$5.41 - $7.3 $ 7.3717%0
John Burbank 2013-06-30 Reduce -51.5%0.38%$4.17 - $5.9 $ 7.3746%1940013
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 62.50
ARAY's Forward P/E is ranked higher than
82% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ARAY: 62.50 )
N/A
P/B 7.52
ARAY's P/B is ranked higher than
60% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. ARAY: 7.52 )
ARAY' s 10-Year P/B Range
Min: 1.1   Max: 11.5
Current: 7.52

1.1
11.5
P/S 1.49
ARAY's P/S is ranked higher than
85% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ARAY: 1.49 )
ARAY' s 10-Year P/S Range
Min: 0.81   Max: 5.99
Current: 1.49

0.81
5.99
EV-to-EBIT -25.91
ARAY's EV-to-EBIT is ranked higher than
51% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 74.50 vs. ARAY: -25.91 )
ARAY' s 10-Year EV-to-EBIT Range
Min: -623.5   Max: 802.9
Current: -25.91

-623.5
802.9
Current Ratio 2.01
ARAY's Current Ratio is ranked higher than
63% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. ARAY: 2.01 )
ARAY' s 10-Year Current Ratio Range
Min: 0.92   Max: 3.13
Current: 2.01

0.92
3.13
Quick Ratio 1.41
ARAY's Quick Ratio is ranked higher than
63% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ARAY: 1.41 )
ARAY' s 10-Year Quick Ratio Range
Min: 0.72   Max: 2.67
Current: 1.41

0.72
2.67
Days Inventory 147.55
ARAY's Days Inventory is ranked higher than
73% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 160.07 vs. ARAY: 147.55 )
ARAY' s 10-Year Days Inventory Range
Min: 70.63   Max: 199.92
Current: 147.55

70.63
199.92
Days Sales Outstanding 60.55
ARAY's Days Sales Outstanding is ranked higher than
87% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. ARAY: 60.55 )
ARAY' s 10-Year Days Sales Outstanding Range
Min: 26.26   Max: 101.57
Current: 60.55

26.26
101.57

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.87
ARAY's Price/Median PS Value is ranked higher than
87% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ARAY: 0.87 )
ARAY' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 3.25
Current: 0.87

0.49
3.25
Earnings Yield (Greenblatt) -3.90
ARAY's Earnings Yield (Greenblatt) is ranked higher than
61% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ARAY: -3.90 )
ARAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 2.9
Current: -3.9

0.1
2.9

Analyst Estimate

Jun15 Jun16
Revenue(Mil) 395 438
EPS($) -0.50 -0.06
EPS without NRI($) -0.50 -0.06

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XEJ.Germany,
Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws.
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
comment on ARAY May 12 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 


More From Other Websites
Accuray (ARAY) Q2 Loss Wider than Expected, Revenues Lag - Analyst Blog Jan 28 2015
Morgan Stanley Goes Over Accuray's Pros And Cons Jan 28 2015
Accuray reports 2Q loss Jan 27 2015
Accuray reports 2Q loss Jan 27 2015
Accuray Inc Earnings Call scheduled for 4:30 pm ET today Jan 27 2015
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 27 2015
Accuray Reports Financial Results for Second Quarter of Fiscal Year 2015 Jan 27 2015
Falling Earnings Estimates Signal Weakness Ahead for Accuray (ARAY) - Tale of the Tape Jan 27 2015
Q2 2015 Accuray Inc Earnings Release - After Market Close Jan 27 2015
Will Accuray (ARAY) Disappoint Earnings Estimates in Q2? - Analyst Blog Jan 23 2015
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 12 2015
Coverage initiated on Accuray by Northland Capital Jan 12 2015
Accuray To Report Results For Second Quarter Fiscal 2015 On January 27, 2015 Jan 12 2015
Accuray To Report Results For Second Quarter Fiscal 2015 On January 27, 2015 Jan 12 2015
Brean Capital Sees Limited 2Q15 Visibility For Accuray Jan 09 2015
ACCURAY INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 07 2015
Accuray to Present at JP Morgan 33rd Annual Healthcare Conference Dec 16 2014
ACCURAY INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 20 2014
Accuray CyberKnife M6 System Now Available in Manhattan Nov 19 2014
First CyberKnife® Full-Body Radiosurgery System in Manhattan Now Treating Patients Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK